Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Thyroid hormone receptor-beta agonists
8 evidence topics · 5 sources
FDA-approved indication and dosage: resmetirom
MAESTRO-NASH week 52 primary end points: 966-patient primary analysis population
EASL-EASD-EASO guideline recommendations: resmetirom in non-cirrhotic MASH with significant fibrosis
EASL-EASD-EASO guideline: response rates, duration of therapy, and use with GLP-1 receptor agonists
AASLD update to the practice guidance: resmetirom patient selection and exclusions
AASLD update to the practice guidance: continuation or discontinuation of resmetirom at 12 months
AASLD update to the practice guidance: resmetirom in persons already receiving other therapies with potential MASH benefit
ADA Standards of Care recommendation 4.28: referral for thyroid hormone receptor-β agonist treatment in adults with type 2 diabetes or prediabetes
“For consideration of treatment with a thyroid hormone receptor-β agonist in adults with type 2 diabetes or prediabetes with MASLD with moderate (F2) or advanced (F3) liver fibrosis on liver histology, or by a validated imaging-based or blood-based test, refer to a gastroenterologist or hepatologist with expertise in MASLD management. A” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given complexities associated with selection of an individual for therapy, drug cost, and treatment monitoring, therapy should be individualized and initiated by a hepatologist or gastroenterologist with expertise in MASH within an interprofessional team.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote